Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report published on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ:EGRX opened at $1.10 on Tuesday. Eagle Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $6.81. The firm has a fifty day simple moving average of $0.80 and a two-hundred day simple moving average of $1.70.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth $59,000. Jane Street Group LLC purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth $96,000. DGS Capital Management LLC grew its stake in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 22,239 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth $453,000. Finally, RBF Capital LLC boosted its stake in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares during the period. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.